Guaifenesin is an expectorant medication used to help loosen mucus in the airways and make coughs more productive.
What is Guaifenesin's Patent Status?
Guaifenesin itself is a well-established medication with expired patents. Its therapeutic uses have been known for decades, and it is available as a generic drug. This means that while specific formulations or combination products might have patent protection, the basic guaifenesin molecule is not under patent [1].
Can Guaifenesin Be Patented?
While the original guaifenesin compound is in the public domain, new and innovative uses or formulations of the drug could potentially be patentable. This could include novel delivery systems, specific combinations with other active ingredients for synergistic effects, or methods of treatment for particular conditions that have not been previously recognized [2]. However, such patents would cover the specific innovation, not guaifenesin as a general substance.
Where Can I Find Information on Drug Patents?
For detailed information on drug patents, including guaifenesin and other medications, resources like DrugPatentWatch.com can be valuable. These platforms track patent expiry dates, litigation, and exclusivity periods for pharmaceutical products [3].
What About Guaifenesin and Cough and Cold Medicine Patents?
Many over-the-counter cough and cold medicines utilize guaifenesin as an active ingredient. While guaifenesin itself is off-patent, manufacturers may hold patents on specific brand-name formulations, such as extended-release versions or combinations with other ingredients like decongestants or antihistamines. These patents protect the specific product's formulation and marketing until their expiry [2][3].
How Long Do Drug Patents Typically Last?
In the United States, a standard drug patent typically lasts for 20 years from the date of filing. However, the effective market exclusivity period can be shorter due to the time required for clinical trials and regulatory approval. For some drugs, extensions can be granted to compensate for patent term lost during this regulatory review process [2].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/